Type 1 diabetes affects nearly 1.45 million Americans, most of whom have to use insulin therapy as a treatment, which is inefficient and can lead to diabetic complications. This project investigates the efficacy of gene editing without immunosuppression as a treatment for type 1 diabetes.
Comparative research will review previous examinations and scientific studies of treatments for factors such as blood sugar levels, hyperglycemic episodes, and overall health. The calculating average blood sugar and hyperglycemic episodes for each treatment group will determine if there is a necessary need for expanding research in this field and if gene editing without immunosuppression is an effective treatment for type 1 diabetes.